ArticleAlzheimer's & dementia (Amsterdam, Netherlands)

Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab.

Ryan Hakim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.